A microRNA carried by plasma extracellular vesicles accelerates the differentiation of B cells into antibody-secreting plasmablasts in bullous pemphigoid (BP), according to in vitro work from Xijing Hospital in Xi'an, China. The team identified miR-148a-3p as the principal EV-borne miRNA driving that shift through BACH2 repression and mTOR activation.

BP is the most common autoimmune subepidermal blistering disease. It produces autoantibodies against components of the epidermal basement membrane, leading to tense blisters and inflammation. Plasmablasts serve as a major source of those pathogenic antibodies, making the molecular switches that govern B-cell-to-plasmablast conversion a central question for BP researchers.

What did the investigators find?

The group, led by Hui Fang of the Department of Dermatology at the Fourth Military Medical University's Xijing Hospital, isolated EV-enriched plasma fractions from 15 newly diagnosed, treatment-naïve BP patients and from healthy controls. The team confirmed the vesicles' cup-shaped morphology by transmission electron microscopy and validated the EV markers CD9, CD63, and CD81 by Western blot and nanoflow cytometry in an initial cohort of n = 3 per group.

Using small-RNA profiling and functional assays, the researchers traced the pathogenic effect to miR-148a-3p, a microRNA packaged inside the vesicles. When BP patient–derived EVs were co-cultured with B cells, miR-148a-3p transferred efficiently into the recipient cells, raising the proportion that differentiated into plasmablasts.

How does miR-148a-3p act on B cells?

The investigators linked the effect to two molecular events. miR-148a-3p reduced expression of BACH2, a transcriptional repressor that restrains plasma-cell differentiation, and activated the mTOR pathway. Together, the dual effect converted B cells into antibody-secreting plasmablasts in culture.

The authors wrote that their data show "plasma-derived EVs from patients with BP are efficiently internalized by B cells," establishing a direct route by which circulating vesicles can shape the autoantibody response in BP.

What are the clinical implications?

The data point to miR-148a-3p and the BACH2–mTOR axis as candidate therapeutic targets. Current first-line treatment relies on topical and systemic corticosteroids, often combined with steroid-sparing immunosuppressants; the steroid burden is especially problematic in elderly patients, who account for most BP cases. A therapy that interrupts the EV–miR-148a-3p–BACH2–mTOR cascade could, in principle, blunt autoantibody production at its source.

The authors caution that the findings rest on in vitro experiments. They call for in vivo validation in BP models and for clinical studies that profile circulating EV cargo in larger, treatment-resistant cohorts.

Who funded the work?

The study received support from the National Natural Science Foundation of China (grants 81903208 and 82173410) and the National Key Research and Development Program of China (grant 2022YFC3601800). The Ethics Committee of the Fourth Military Medical University approved the protocol (KY20172030-1) in line with the Declaration of Helsinki. The authors declared no conflicts of interest. Hui Fang is the guarantor of the article.

Looking ahead, the team is expected to test whether blocking miR-148a-3p uptake—or inhibiting mTOR in B cells—can reduce autoantibody titers in preclinical BP models, a step that would determine whether the cascade identified here is druggable in patients.